First-line therapy for chronic myeloid l
✍
Carolina Pavlovsky; Hagop Kantarjian; Jorge E. Cortes
📂
Article
📅
2009
🏛
John Wiley and Sons
🌐
English
⚖ 326 KB
## Abstract The development of Bcr‐Abl tyrosine kinase inhibitors has dramatically changed the prognosis of patients with newly diagnosed chronic myeloid leukemia (CML). Standard‐dose imatinib (400 mg/day in chronic phase, 600 mg/day in advanced CML) now dominates the management of this disease, pr